Articles tagged "Monitoring"

2021 American Transplant Congress
Donor Derived Cell-free DNA Kinetics Early After Kidney Transplant in Patients with Delayed Graft Function Who Received Kidneys from Donation After Cardiac Death Donors
R. Gumber, M. Abuzeineh, C. Mejia, D. Brennan, F. Naqvi
Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Delayed graft function (DGF) may reduce long-term kidney allograft survival due to ischemia-reperfusion injury and rejection. Donor Derived Cell-Free DNA (dd-cfDNA) is proposed to…
2021 American Transplant Congress
Immunologic Endotypes of Ischemia-reperfusion Injury in Human Liver Transplantation
R. A. Sosa, A. Q. Terry, F. M. Kaldas, B. V. Naini, T. Ito, R. W. Busuttil, D. W. Gjertson, J. W. Kupiec-Weglinski, E. F. Reed
UCLA, Los Angeles, CA
*Purpose: Ischemia-reperfusion injury (IRI) is a major risk factor for allograft rejection in orthotopic liver transplantation (OLT), involving complex interactions between innate and adaptive immune…
2021 American Transplant Congress
Donor-Derived Cell-Free DNA as a Surrogate Marker for “Allograft Quiescence” After Kidney Transplantation
J. S. Bromberg¹, L. Bu², G. Gupta³, I. Moinuddin³, S. Anand⁴, A. Pai⁵, T. Alhamad⁶, V. Bowers⁷, S. Ghosh⁸, W. Tian⁸, E. Stites⁹
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Minnesota, Minneapolis, MN, ³Virginia Commonwealth University, Richmond, VA, ⁴Intermountain Medical Center, Murray, UT, ⁵University of Texas McGovern Medical School, Houston, TX, ⁶Washington University in St. Louis, St. Louis, MO, ⁷Tampa General Hospital, Tampa, FL, ⁸CareDx, Brisbane, CA, ⁹University of Colorado, Aurora, CO
*Purpose: Donor-derived cell-free DNA (dd-cfDNA; AlloSure®) and the association with active rejection (AR) was described by Bloom et al, however subsequent insights have suggested this…
2021 American Transplant Congress
High Donor-Derived Cell-Free DNA Levels Predict Development of De Novo HLA Donor-Specific Antibodies After Kidney Transplantation – Data from the ADMIRAL Study
G. Gupta¹, T. Alhamad², V. Bowers³, I. Moinuddin¹, S. Ghosh⁴, J. Zeng⁴, E. Stites⁵, A. Pai⁶, J. S. Bromberg⁷, S. Anand⁸
¹Virginia Commonwealth University, Richmond, VA, ²Washington University in St. Louis, St. Louis, MO, ³Tampa General Hospital, Tampa, FL, ⁴CareDx, Brisbane, CA, ⁵University of Colorado, Aurora, CO, ⁶University of Texas McGovern Medical School, Houston, TX, ⁷University of Maryland School of Medicine, Baltimore, MD, ⁸Intermountain Medical Center, Murray, UT
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) as a marker of injury can serve to quantify subclinical inflammation and molecular injury. As the release of graft genomic…
2021 American Transplant Congress
Solid Organ Transplant Telehealth Utilization Significantly Increased During the Covid-19 Pandemic: Experience at a Single, Large Volume Center
R. Forbes, K. Kumm, H. O'Dell, K. Smith, L. Smith, A. Dreher, H. Schaefer, B. Concepcion
Vanderbilt University Medical Center, Nashville, TN
*Purpose: During the COVID-19 pandemic, telehealth utilization has allowed for the delivery of healthcare while protecting patients, caregivers, healthcare workers, and the community from exposure.…
2021 American Transplant Congress
Novel Mixed Lymphocyte Reaction Monitoring System That Predicts Chronic Antibody- Mediated Rejection in Kidney Transplant Recipients
N. Iwahara¹, K. Hotta¹, T. Tanabe¹, D. Iwami², Y. Takada³, H. Higuchi¹, H. Sasaki³, H. Harada³, N. Shinohara¹
¹Hokkaido Univercity, Sapporo, Japan, ²Jichi Medical University, Shimotsuke, Japan, ³Sapporo City General Hospital, Sapporo, Japan
*Purpose: Chronic active antibody-mediated rejection (CAAMR) induced by de novo donor-specific antibodies (DSA) is the main cause of graft loss in the long-term. Currently, there…
2021 American Transplant Congress
Are Tacrolimus Concentrations Reduced with Direct-acting Antiviral Administration in Transplant Recipients?
K. Huang, K. Farrow, M. Christian
Pharmacy, Penn State Health Hershey Medical Center, Hershey, PA
*Purpose: To evaluate the effects of direct-acting antivirals (DAAs) on tacrolimus trough concentrations and clinical outcome and to assess the need for a priori dose…
2021 American Transplant Congress
Tacrolimus Shortage and the Rush to Convert: An Unexpected Burden on the System During the Covid-19 Pandemic?
N. Pilch, L. Johnson, M. Aldoughaim, N. Patel, F. Bartlett
Medical University of South Carolina, Charleston, SC
*Purpose: A national shortage of immediate release (IR) tacrolimus (FK) fully impacted our center in May 2020. The conversion process was immediately challenging during the…
2021 American Transplant Congress
Determining Endpoint Criteria in Ex Vivo Normothermic Limb Perfusion (EVNLP)
S. K. Pandey¹, A. Meyers¹, P. Sadeghi¹, V. Kopparthy¹, T. Xia¹, H. Brunengraber², S. Dasarathy³, A. Rampazzo¹, B. Bassiri Gharb¹
¹Plastic Surgery, Cleveland Clinic, Cleveland, OH, ²Department of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, OH, ³Department of Gastroenterology, Cleveland Clinic, Cleveland, OH
*Purpose: There are no established criteria for discontinuing EVNLP before irreversible muscle and endothelial cell damage occur. This study aimed to evaluate weight gain as…
2020 American Transplant Congress
Evaluation of the Use of Sublingual Tacrolimus in the Inpatient Setting
K. Szempruch¹, L. Kemp¹, A. Barber¹, S. Mason¹, G. Offei-Nkansah¹, D. Gerber², P. Owen¹
¹Pharmacy, UNC Medical Center, Chapel Hill, NC, ²Surgery-Transplant, UNC Medical Center, Chapel Hill, NC
*Purpose: To determine the efficacy and safety of sublingual (SL) tacrolimus (TAC) administration.*Methods: A single-center, retrospective study was performed on solid organ transplant recipients who…

« Previous Page
1
…
4
5
6
7
8
…
22
Next Page »